Cite
MLA Citation
Khalil Zaman et al.. “Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.” European journal of cancer, vol. 51, no. 10, n.d., pp. 1212–1220. http://access.bl.uk/ark:/81055/vdc_100025913420.0x000002